戻る
Briacell Therapeutics Corp (BCTX)価格
BCTX 株価推移チャート
BCTX 収入
Briacell Therapeutics Corp
$4.29
-4.45%
$-0.2
終値： Jan 16, 16:00:00 GMT-5
$4.37
1.86%
$0.08
アフターマーケット：Jan 16, 20:00:00 GMT-5
主要データ
前終値
$4.49
始値
$4.5
当日レンジ
$4.12 - $4.52
52週レンジ
$3.5 - $98.2
取引高
749.1K
平均取引高
305.7K
1株当たり利益(TTM)
-33.87
配当利回り
--
時価総額
$8.2M
BriaCell Therapeutics Corp.とは何ですか？
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. The company is headquartered in West Vancouver, British Columbia and currently employs 20 full-time employees. The company went IPO on 2006-10-12. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.